Alora Pharmaceuticals Highlights RELEXXII for ADHD Care

ALPHARETTA, Ga., October 6, 2026

ADHD Awareness Highlights Need for Individualized Care

October marks ADHD Awareness Month, bringing attention to the prevalence of ADHD and the importance of timely diagnosis and personalized treatment. According to the information provided by Alora Pharmaceuticals, approximately 11.7% of children and adolescents in the United States have been diagnosed with ADHD, while adult diagnoses are estimated at around 6%. ADHD can involve persistent patterns of inattention, hyperactivity, and impulsivity, which may affect daily functioning across different stages of life. The company also highlights the need to recognize differences in how ADHD may present among individuals. Symptoms can vary considerably, and some people, including women, may experience symptoms that are less visible or more easily overlooked. These differences reinforce the importance of individualized assessment and ongoing communication between patients and healthcare professionals when determining appropriate treatment approaches. For people diagnosed with ADHD, selecting an appropriate medication and dose is an important component of treatment management. Alora Pharmaceuticals emphasizes precision dosing and ongoing medication optimization, particularly because individual responses to treatment can vary.

RELEXXII Supports Flexible Methylphenidate Dosing

RELEXXII contains methylphenidate hydrochloride in an extended-release tablet formulation and is positioned by the company as a once-daily treatment option for ADHD. Alora Pharmaceuticals highlights the availability of multiple tablet strengths as an important feature that can give healthcare providers greater flexibility when adjusting treatment. Careful dose optimization of methylphenidate has been associated with meaningful symptom-management benefits, particularly in children, according to the company’s cited research. The availability of different strengths can support clinicians as they evaluate treatment response and make adjustments based on individual patient needs. Alora Pharmaceuticals CEO Art Deas said the company is committed to supporting the ADHD community and advancing therapies that can make a meaningful difference in everyday life. The company emphasizes that healthcare providers remain central to diagnosis and treatment decisions, while its role is to provide pharmaceutical options that support individualized care.

Alora Expands Specialty Pharmaceutical Portfolio

Alora Pharmaceuticals, headquartered in Alpharetta, Georgia, is a pharmaceutical company focused on quality, reliability, and affordability. The company serves as the parent organization for seven specialty pharmaceutical and pharmaceutical manufacturing businesses, including Vertical Pharmaceuticals, the company associated with RELEXXII. Its broader organization includes operations and manufacturing facilities in Texas and Georgia. The company reports that the Alora family of businesses employs more than 550 people and manufactures medicines in the United States, supporting domestic pharmaceutical production and supply-chain resilience. RELEXXII is a registered trademark of Vertical Pharmaceuticals, LLC. The company’s ADHD Awareness Month campaign also emphasizes the importance of conversations between individuals experiencing ADHD symptoms and qualified healthcare professionals. Treatment decisions, including medication selection and dose adjustments, should be guided by healthcare providers based on each patient’s clinical needs. By highlighting RELEXXII, once-daily extended-release methylphenidate, and precision dosing, Alora Pharmaceuticals is drawing attention to the importance of individualized ADHD management. The company’s focus on multiple tablet strengths and treatment optimization reflects the broader pharmaceutical effort to provide flexible options for patients whose ADHD symptoms and treatment responses can differ significantly.

Source: Alora Pharmaceuticals press release